The Latest Cardiac and Vascular News
Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning from Tyvaso® Inhalation Solution A separate study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution Tyvaso DPI NDA filing anticipated in April 2021 with priority review SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, […]
– Second quarter Orenitram® revenue growth of 40% year-over-year – INCREASE sNDA submitted to FDA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 29, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2020. “I am pleased with our performance during the second quarter, and […]
– First quarter Orenitram® net revenue growth of 18% year-over-year – Major milestones such as the INCREASE filing and Remunity™ Pump launch remain on track despite the COVID-19 pandemic – United Therapeutics is engaged in the fight against COVID-19 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 29, 2020 /PRNewswire/ — United Therapeutics […]
– Orenitram demonstrated improvement in hemodynamic parameters and risk status, important indicators of long-term outcomes in PAH patients, in presentations at recent scientific conferences – Separately, total PAH-related patient healthcare costs are 67% higher for selexipag in article published in Drugs – Real World Outcomes SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, […]
